<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164009">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00962949</url>
  </required_header>
  <id_info>
    <org_study_id>081398</org_study_id>
    <secondary_id>PF334</secondary_id>
    <nct_id>NCT00962949</nct_id>
  </id_info>
  <brief_title>The Renin-Aldosterone Axis in Postural Tachycardia Syndrome</brief_title>
  <official_title>The Renin-Aldosterone Axis in Postural Tachycardia Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the role of the renin-angiotensin-aldosterone in
      the pathophysiology of postural tachycardia syndrome, and to provide an insight about the
      disease process in this disorder.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">April 2011</completion_date>
  <primary_completion_date type="Anticipated">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in blood pressure rise between patients and healthy volunteers</measure>
    <time_frame>1 hour</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in blood volume hormones responses between patients and healthy volunteers</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Postural Tachycardia Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy controls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Angiotensin II</intervention_name>
    <description>Angiotensin II infusion for 1 hour</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of postural tachycardia syndrome by the Vanderbilt Autonomic Dysfunction
             Center criteria

          -  Age between 18-64 years

          -  Male or females are eligible

          -  Able and willing to provide informed consent

          -  Healthy control subjects with no major medical problem (including postural
             tachycardia syndrome), free of medications during the study

        Exclusion Criteria:

          -  Overt cause of postural tachycardia e.g., dehydration

          -  Inability to give or withdraw informed consent

          -  Pregnancy

          -  Hypertension (BP &gt; 140/90)

          -  Significant co-morbid condition

          -  Other factors which in the investigator`s opinion would prevent the subject from
             completing the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bonnie Black, RN</last_name>
    <phone>615-343-6862</phone>
    <email>bonnie.black@Vanderbilt.Edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ginnie Farley, RA</last_name>
    <phone>615-322-0083</phone>
    <email>ginnie.farley@Vanderbilt.Edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Robertson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hossam Mustafa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <lastchanged_date>August 19, 2009</lastchanged_date>
  <firstreceived_date>August 18, 2009</firstreceived_date>
  <responsible_party>
    <name_title>Hossam Mustafa MD</name_title>
    <organization>Vanderbilt University school Of Medicine</organization>
  </responsible_party>
  <keyword>POTS</keyword>
  <keyword>Orthostatic intolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Postural Orthostatic Tachycardia Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Angiotensinogen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
